KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Deferred Revenue: 2009-2016

Historic Current Deferred Revenue for Acadia Pharmaceuticals (ACAD) over the last 6 years, with Dec 2016 value amounting to $2.6 million.

  • Acadia Pharmaceuticals' Current Deferred Revenue was N/A to $4.1 million in Q1 2017 from the same period last year, while for Mar 2017 it was $4.1 million, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2016, which is N/A change from last year.
  • As of FY2016, Acadia Pharmaceuticals' Current Deferred Revenue stood at $2.6 million, which was up 4,707.27% from $55,000 recorded in FY2013.
  • Acadia Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $2.6 million during FY2016, with a 5-year trough of $55,000 in FY2013.
  • In the last 1 years, Acadia Pharmaceuticals' Current Deferred Revenue had a median value of $2.6 million in 2016 and averaged $2.6 million.
  • Data for Acadia Pharmaceuticals' Current Deferred Revenue shows a maximum YoY tumbled of 87.33% (in 2013) over the last 5 years.
  • Acadia Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $434,000 in 2012, then crashed by 87.33% to $55,000 in 2013, then reached $2.6 million in 2016.